Compare AMST & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMST | SILO |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Apparel |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.1M |
| IPO Year | 2020 | 2011 |
| Metric | AMST | SILO |
|---|---|---|
| Price | $0.54 | $1.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 31.0K | 21.9K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.83 | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $364,777.00 | $72,102.00 |
| Revenue This Year | $19,089.81 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230.24 | N/A |
| 52 Week Low | $0.52 | $1.10 |
| 52 Week High | $3.05 | $10.43 |
| Indicator | AMST | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 19.50 | 43.90 |
| Support Level | N/A | $1.30 |
| Resistance Level | $1.11 | $1.38 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 13.20 | 81.10 |
Amesite Inc is a technology company focused on building and commercializing AI (artificial intelligence)-powered solutions for the enterprise and for professionals, with particular emphasis on the post-acute healthcare market. It operates through two product lines: NurseMagic and LynkMagic. NurseMagic solutions include a B2B (business-to-business) enterprise application and a B2C (business-to-consumer) solution for individual healthcare professionals. LynkMagic provides enterprise AI solutions for healthcare and related organizations. Its products support documentation, workflow, compliance, oversight, and are designed to improve operational quality and efficiency. It has one single operating and reporting segment, B2C and B2B AI-driven solutions.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.